BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA ) with a Buy rating and announces Price Target of $34.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.